Topological alterations in older adults with temporal lobe epilepsy are distinct from amnestic mild cognitive impairment
Abstract
Epilepsy incidence and prevalence peaks in older adults, yet systematic studies of brain aging and epilepsy remain limited. We investigated topological network disruption in older adults with temporal lobe epilepsy (TLE; age > 55 years). Additionally, we examined the potential network disruption overlap between TLE and amnestic mild cognitive impairment (aMCI), the prodromal stage of Alzheimer disease. Measures of network integration (“global path efficiency”) and segregation (“transitivity” and “modularity”) were calculated from cortical thickness covariance from 73 TLE subjects, 79 aMCI subjects, and 70 healthy controls. Compared to controls, TLE patients demonstrated abnormal measures of segregation (increased transitivity and decreased modularity) and integration (decreased global path efficiency). aMCI patients also displayed increased transitivity and decreased global path efficiency, but these differences were less pronounced than in TLE. At the local level, TLE patients demonstrated decreased local path efficiency focused in the bilateral temporal lobes, whereas aMCI patients had a more frontal‐parietal distribution. These results suggest that network disruption at the global and local level is present in both disorders, but global disruption may be a particularly salient feature in older adults with TLE. These findings motivate further research into whether these network changes have distinct cognitive correlates or are progressive in older adults with epilepsy.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Oct 14, 2020
- Source ID
- 10.1111/epi.16703
Entities
People
- Anny Reyes
- Bruce P Hermann
- Carrie R. Mcdonald
- Daniel L Drane
- Erik Kaestner
- For The Alzheimer’s Disease Neuroimaging Initiative*
- Robyn M Busch
- Vineet Punia
- Z I Wang
Organizations
- AbbVie
- Alzheimer's Association
- Alzheimer's Drug Discovery Foundation
- BioClinica
- Biogen
- Bristol-Myers Squibb
- Eisai
- Eli Lilly and Company
- Emory University
- GE HealthCare
- Innogenetics
- Merck & Co.
- Meso Scale Diagnostics (United States)
- National Institute of Biomedical Imaging and Bioengineering
- National Institute of Neurological Disorders and Stroke
- National Institute on Aging
- National Institutes of Health
- Northern California Institute for Research and Education
- Novartis
- Perrigo Company Plc
- Pfizer
- San Diego State University
- Takeda Pharmaceutical Company
- United States Department of Defense
- University of California, San Diego
- University of Washington
- University of Wisconsin–Madison